Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy

Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28.

Abstract

No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.

Keywords: antibodies; cancer immunotherapy; immune checkpoint; programmed death 1; protein-protein interactions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • B7-H1 Antigen / immunology
  • Humans
  • Immunotherapy
  • Models, Molecular
  • Molecular Targeted Therapy
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor / immunology*

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor